Cargando…
Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study
BACKGROUND: Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection. We evaluated the efficacy and safety of secnidazole vs placebo in women with trichomoniasis. METHODS: Women with trichomoniasis, confirmed by a positive T. vaginalis culture, were randomized to single-do...
Autores principales: | Muzny, Christina A, Schwebke, Jane R, Nyirjesy, Paul, Kaufman, Gregory, Mena, Leandro A, Lazenby, Gweneth B, Van Gerwen, Olivia T, Graves, Keonte J, Arbuckle, Janeen, Carter, Belvia A, McMahon, Connette P, Eder, Scott, Shaw, Jackie, Pandey, Brajesh, Chavoustie, Steven E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442793/ https://www.ncbi.nlm.nih.gov/pubmed/33768237 http://dx.doi.org/10.1093/cid/ciab242 |
Ejemplares similares
-
Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data
por: Muzny, Christina A, et al.
Publicado: (2023) -
Successful Treatment of Persistent 5-Nitroimidazole–Resistant Trichomoniasis With an Extended Course of Oral Secnidazole Plus Intravaginal Boric Acid
por: McNeil, Candice J., et al.
Publicado: (2023) -
Cost-Effective Screening for Trichomoniasis
por: Schwebke, Jane R.
Publicado: (2002) -
Trichomoniasis: An update
por: Preethi, V, et al.
Publicado: (2011) -
Vaginal trichomoniasis
por: Cenkowski, Monica, et al.
Publicado: (2022)